PatientsVille.com Logo


Panadol osteo Medical Research Studies

Up-to-date List of Panadol osteo Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Panadol osteo Medical Research Studies

Rank Status Study
1 Recruiting Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding
Conditions: Colorectal Cancer;   Rectal Bleeding
Intervention: Drug: Desmopressin
Outcome Measures: Presence or absence of grade 3 or 4 adverse events related to the study drug, in a maximum of 2 out of 6 patients assessed in each dose level.;   Number of patients with grade 3 or 4 local adverse events;   Number of patients with grade 3 or 4 systemic adverse events;   Number of withdrawn from treatment;   Number of patients with partial or complete response in clinical endpoints
2 Not yet recruiting Trial of Argon Plasma Coagulation Versus APC and APC and Hemospray in the Treatment of Radiation Proctitis
Condition: Rectal Bleeding
Intervention: Other: Hemospray
Outcome Measures: cessation of rectal bleeding;   number of treatments required to achieve cessation of Rectal Bleeding
3 Recruiting A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors
Condition: Ulcerative Colitis
Interventions: Drug: etrolizumab;   Drug: infliximab;   Other: placebo (injection);   Other: placebo (IV)
Outcome Measures: Proportion of patients in sustained remission as determined by Mayo Clinic Score (MCS). Sustained remission is defined as MCS </=2 with individual subscores </=1 and a Rectal Bleeding subscore of 0 sustained at each of the Week 10, 30, and 54 assessments;   Proportion of patients achieving remission, defined as MCS </=2 with individual subscores </=1 and a Rectal Bleeding subscore of 0;   Proportion of patients achieving clinical response, defined as MCS with >/=3-point decrease and 30% reduction from baseline as well as >/=1-point decrease in Rectal Bleeding subscore or an absolute Rectal Bleeding score of 0 or 1;   Proportion of patients achieving sustained clinical response, defined by clinical response sustained at Weeks 10, 30, and 54
4 Recruiting NIRS and Doppler to Predict NEC in Risk Neonates
Condition: Necrotizing Enterolitis
Intervention: Device: Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler
Outcome Measures: Cerebro-splanchnic oxygenation ratio;   Mesenteric Doppler flow
5 Recruiting Colonic Capsule Endoscopy (CCE) for Screening of Neoplasm's A Pilot Study
Condition: Rectal Bleeding
Intervention: Device: Pillcam® COLON Capsule
Outcome Measure: Number of patients with neoplasia
6 Recruiting Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
Conditions: Abdominal Pain;   Rectal Bloodloss;   Diarrhea;   Inflammatory Bowel Disease;   Crohn's Disease;   Ulcerative Colitis;   Irritable Bowel Syndrome
Outcome Measures: Proportion of patients with non-inflammatory conditions among the total number of patient subjected to endoscopy;   Test accuracy
7 Unknown  Is Doppler Necessary in Haemorrhoidal Artery Ligation Operation?
Conditions: Piles;   Bleeding
Intervention: Procedure: HALO
Outcome Measures: Improvement of rectal bleeding;   Satisfaction with the HALO procedure with or without doppler guidance
8 Recruiting Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer
Condition: Prostate Cancer
Interventions: Radiation: 70 Gy/CGE;   Radiation: 72.5 Gy/CGE
Outcome Measures: Cumulative incidence of treatment-related grade 2 or higher Rectal Bleeding.;   Analyzation of quality of life;   Analysis of treatment-related morbidity, disease control, survival outcome parameters
9 Recruiting Survey: Clinical Outcome After Bowel Resection in Women Due to Endometriosis
Condition: Bowel Endometriosis
Intervention: Procedure: laparoscopic colonic surgery
Outcome Measures: pain;   dyspareunia;   dysuria;   obstipation;   pain during defecation;   rectal bleeding
10 Recruiting Efficacy Study of Prophylaxis With Fosfomycin Versus Ciprofloxacin Prior Prostate Biopsy
Condition: Urinary Tract Infections
Interventions: Drug: Fosfomycin 3 g;   Drug: Ciprofloxacin 500 mg
Outcome Measures: Bacteriuria;   Urinary Tract Infection;   Sepsis;   Pathogens present in urine and antimicrobial resistance;   Bacteremia;   Hematuria;   Hemospermia;   Rectal bleeding;   Urinary retention;   Difficulty for miction;   Genitourinary infections associated to fever (>38ºC);   Number of participants with adverse events
11 Recruiting In Vivo Dosimetry During Prostate Cancer Radiotherapy
Condition: Prostate Disease
Intervention: Device: Plastic Scintillation Detectors
Outcome Measure: Measurement of True In Vivo Radiation to Rectal Wall During Prostate Radiotherapy
12 Not yet recruiting Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Apremilast;   Drug: Placebo
Outcome Measures: Proportion of subjects achieving a clinical remission in;   The proportion of subjects achieving clinical response at Week 12;   The proportion of subjects achieving endoscopic remission at Week 12, defined as a Mayo endoscopic subscore of 0;   The proportion of subjects achieving endoscopic response at Week 12, defined as a decrease from baseline of at least 1 point in the Mayo endoscopic subscore;   The proportion of subjects achieving a Rectal Bleeding Score (RBS) ≤ 1 at Week 12;   The proportion of subjects achieving clinical remission in the modified Mayo Score (range: 0 to 9, based on stool frequency subscore (SFS), RBS and endoscopy) at Week 12;   The proportion of subjects achieving clinical response in the modified Mayo Score at Week 12;   The proportion of subjects achieving clinical remission at Week 8;   The proportion of subjects achieving clinical response at Week 8;   Adverse Events; Type, frequency, severity, and relationship of AEs to IP, AE leading to discontinuation, clinical significant change in vital sign and / or lab, and in weight and ECG
13 Not yet recruiting Feasibility of Superior Rectal Artery Embolization for the Treatment of Hemorrhoidal Disease
Condition: Hemorrhoidal Disease
Intervention: Device: NESTER COILS
Outcome Measures: Decrease  of the felt pain;   Reaaparition or obstinacy of the hemorroidal symptoms
14 Unknown  Safety, Tolerability, Biomarker and Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis
Conditions: Left-Sided Ulcerative Colitis;   Proctosigmoiditis
Interventions: Drug: PUR 0110 Rectal Enema 250 mg;   Drug: PUR 0110 Rectal Enema 500 mg;   Drug: PUR 0110 Rectal Enema 1000 mg;   Drug: Placebo Enema
Outcome Measure: Incidence, nature and severity of adverse events and abnormal clinical laboratory test results
15 Unknown  Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
Conditions: Esophagitis;   Colitis
Outcome Measure:
16 Recruiting Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients
Condition: Colitis, Ulcerative
Interventions: Drug: SB012;   Drug: Placebo
Outcome Measures: Efficacy: Total Mayo score (4 weeks comparison);   Efficacy: Total Mayo score (8 weeks comparison);   Efficacy: Endoscopic Mayo score (4 and 8 weeks comparison);   Efficacy/Pharmacodynamics: Glucocorticoid consumption;   Safety: Treatment Emergent Adverse Events (AE) and Serious Adverse Events (SAE)
17 Recruiting Gut Microbiota in the Healthy Population, Inflammatory Bowel Disease Patients, and Their Relatives
Condition: Inflammatory Bowel Disease
Outcome Measures: To identify specific gut microbiota in IBD patients;   To identify environmental risk factors;   To identify genetic differences among IBD patients, their relatives and the control subjects;   To identify disease characteristics among IBD patients
18 Recruiting Rectal Misoprostol and Blood Loss During Abdominal Hysterectomy
Condition: Blood Loss
Interventions: Drug: Misoprostol;   Drug: Placebo
Outcome Measures: Blood loss;   postoperative hemoglobin level
19 Recruiting Recto Colonic Endoscopic Mucosal Resection and Polypectomy Under Clopidogrel
Condition: Polyps
Intervention: Procedure: Colonic polypectomy or endoscopic mucosal resection (EMR).
Outcome Measures: Incidence of delayed bleeding after polypectomy and / or colonic mucosectomy;   Incidence of immediate bleeding after polypectomy and / or colonic mucosectomy;   Incidence of severe bleeding after polypectomy and / or colonic mucosectomy in patients on Clopidogrel;   Efficacy of endoscopic hemostasis in case of bleeding induced;   morbidity / mortality induced by immediate and delayed bleeding after polypectomy and / or colonic mucosectomy in patients on clopidogrel;   predictors of gastrointestinal bleeding post polypectomy / mucosectomy under clopidogrel by sub groups of patients obtained
20 Not yet recruiting The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin
Condition: Gastrointestinal Hemorrhage
Interventions: Drug: Aspirin (ASA);   Drug: Placebo
Outcome Measures: Clinically significant bleeding after colorectal polypectomy;   Proportion of composite cardiovascular events, ending unplanned hospitalization in both groups aspirin and placebo;   Proportion of clinically significant delayed bleeding in both groups

These studies may lead to new treatments and are adding insight into Panadol osteo etiology and treatment.

A major focus of Panadol osteo research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Panadol osteo